ADRB2 and non-small cell lung carcinoma: However, blocking the ADRB2/CREB/PSAT1 axis enhanced the sensitivity of NSCLC to VEGFR2-TKIs and provided a novel promising combinatory approach to enhance the antitumor effect of VEGFR2-TKIs in NSCLC.